valproic acid has been researched along with Brain Ischemia in 23 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 8.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| " The antiepileptic drug valproic acid (VPA) was reported to protect cerebral ischemia/reperfusion injury." | 7.91 | Valproic acid attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-pyroptosis pathways. ( Cheng, YY; Guan, L; Jia, LQ; Liu, Y; Min, DY; Song, N; Wang, LJ; Yang, GL; Yang, YJ; Zhan, KX; Zhang, Z; Zhu, S, 2019) |
| "Valproic acid (VA) is an antiepileptic that is also used for the treatment of bipolar disorders." | 5.48 | Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. ( Correia, AO; Costa, RO; da Silva Ribeiro, AE; de Barros Viana, GS; de Siqueira, KP; Dos Santos, GCA; Lima, DGS; Lucetti, DL; Lucetti, ECP; Moura, JA; Neves, KRT; Parente, LLT; Silva, MR, 2018) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 5.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 4.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| " The antiepileptic drug valproic acid (VPA) was reported to protect cerebral ischemia/reperfusion injury." | 3.91 | Valproic acid attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-pyroptosis pathways. ( Cheng, YY; Guan, L; Jia, LQ; Liu, Y; Min, DY; Song, N; Wang, LJ; Yang, GL; Yang, YJ; Zhan, KX; Zhang, Z; Zhu, S, 2019) |
| "Mice were subjected to middle cerebral artery occlusion (MCAO) model to induce IS injures and then were administrated with VPA." | 1.56 | Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis. ( Li, X; Sui, Y, 2020) |
| "Valproic acid (VA) is an antiepileptic that is also used for the treatment of bipolar disorders." | 1.48 | Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. ( Correia, AO; Costa, RO; da Silva Ribeiro, AE; de Barros Viana, GS; de Siqueira, KP; Dos Santos, GCA; Lima, DGS; Lucetti, DL; Lucetti, ECP; Moura, JA; Neves, KRT; Parente, LLT; Silva, MR, 2018) |
| "Hyperglycemia was induced by streptozotocin (STZ) injection 3 days before." | 1.42 | Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion. ( Abe, A; Aoki, J; Kimura, K; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Suda, S; Suzuki, K; Ueda, M, 2015) |
| "Male rats underwent middle cerebral artery occlusion for 60 minutes followed by reperfusion for up to 14 days." | 1.38 | Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. ( Chibane, F; Chuang, DM; Fessler, EB; Leeds, P; Leng, Y; Munasinghe, J; Tsai, LK; Wang, Z, 2012) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 1.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| " In patients with heterozygote (MTHFR) 677C/T polymorphism and under long-term use of certain drugs the determination of Hcy plasma levels may be useful to prevent the development of atherothrombotic disease." | 1.35 | Na VPA-induced acute ischemic stroke in an epileptic patient with methylenetetrahydrofolate reductase gene polymorphism. ( Varoglu, AO, 2009) |
| "Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients." | 1.34 | Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. ( Chen, PS; Chuang, DM; Hong, JS; Kim, HJ; Ren, M; Rowe, M, 2007) |
| "When phenytoin was discontinued, valproate levels increased, and he progressively improved." | 1.30 | Exceptionally long absence status: multifactorial etiology, drug interactions and complications. ( Andermann, F; Bastos, A; D'Agostino, MD; Dubeau, F; Fedi, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Zeb, S | 1 |
| He, YY | 1 |
| Guo, Y | 1 |
| Zhu, YM | 1 |
| Zhou, XY | 1 |
| Zhang, HL | 1 |
| Naseh, M | 1 |
| Bayat, M | 1 |
| Akbari, S | 1 |
| Vatanparast, J | 1 |
| Shabani, M | 1 |
| Haghighi, AB | 1 |
| Haghani, M | 1 |
| Li, X | 1 |
| Sui, Y | 1 |
| Brookes, RL | 1 |
| Crichton, S | 1 |
| Wolfe, CDA | 1 |
| Yi, Q | 1 |
| Li, L | 1 |
| Hankey, GJ | 1 |
| Rothwell, PM | 1 |
| Markus, HS | 2 |
| Silva, MR | 1 |
| Correia, AO | 1 |
| Dos Santos, GCA | 1 |
| Parente, LLT | 1 |
| de Siqueira, KP | 1 |
| Lima, DGS | 1 |
| Moura, JA | 1 |
| da Silva Ribeiro, AE | 1 |
| Costa, RO | 1 |
| Lucetti, DL | 1 |
| Lucetti, ECP | 1 |
| Neves, KRT | 1 |
| de Barros Viana, GS | 1 |
| Bolland, MJ | 1 |
| Avenell, A | 1 |
| Gamble, G | 1 |
| Grey, A | 1 |
| Hernández de G, MM | 1 |
| Garay F, JL | 1 |
| Loureiro, NE | 1 |
| Zhu, S | 1 |
| Zhang, Z | 1 |
| Jia, LQ | 1 |
| Zhan, KX | 1 |
| Wang, LJ | 1 |
| Song, N | 1 |
| Liu, Y | 1 |
| Cheng, YY | 1 |
| Yang, YJ | 1 |
| Guan, L | 1 |
| Min, DY | 1 |
| Yang, GL | 1 |
| Suda, S | 3 |
| Katsura, K | 1 |
| Kanamaru, T | 1 |
| Saito, M | 2 |
| Katayama, Y | 2 |
| Belozertsev, IuA | 1 |
| Zapol'skaia, IuA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Katsura, KI | 1 |
| Kamiya, N | 1 |
| Dregan, A | 1 |
| Charlton, J | 1 |
| Wolfe, CD | 1 |
| Gulliford, MC | 1 |
| Merson, TD | 1 |
| Bourne, JA | 1 |
| Ueda, M | 1 |
| Nito, C | 1 |
| Nishiyama, Y | 1 |
| Okubo, S | 1 |
| Abe, A | 1 |
| Aoki, J | 1 |
| Suzuki, K | 1 |
| Sakamoto, Y | 1 |
| Kimura, K | 1 |
| Varoglu, AO | 1 |
| Mink, S | 1 |
| Muroi, C | 1 |
| Seule, M | 1 |
| Bjeljac, M | 1 |
| Keller, E | 1 |
| Das, S | 1 |
| Joardar, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hashmi, MA | 1 |
| Wang, Z | 1 |
| Tsai, LK | 1 |
| Munasinghe, J | 1 |
| Leng, Y | 1 |
| Fessler, EB | 1 |
| Chibane, F | 1 |
| Leeds, P | 1 |
| Chuang, DM | 2 |
| Costa, C | 1 |
| Martella, G | 1 |
| Picconi, B | 1 |
| Prosperetti, C | 1 |
| Pisani, A | 1 |
| Di Filippo, M | 1 |
| Pisani, F | 1 |
| Bernardi, G | 1 |
| Calabresi, P | 1 |
| Vorbrodt, AW | 1 |
| Dobrogowska, DH | 1 |
| Kozlowski, PB | 1 |
| Rabe, A | 1 |
| Tarnawski, M | 1 |
| Lee, MH | 1 |
| Kim, HJ | 1 |
| Rowe, M | 1 |
| Ren, M | 1 |
| Hong, JS | 1 |
| Chen, PS | 1 |
| Ibrahim, S | 1 |
| Hyder, SS | 1 |
| D'Agostino, MD | 1 |
| Andermann, F | 1 |
| Dubeau, F | 1 |
| Fedi, M | 1 |
| Bastos, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
1 review available for valproic acid and Brain Ischemia
| Article | Year |
|---|---|
Endogenous neurogenesis following ischaemic brain injury: insights for therapeutic strategies.
Topics: Adult; Animals; Brain Injuries; Brain Ischemia; Histone Deacetylase Inhibitors; Humans; Nerve Regene | 2014 |
1 trial available for valproic acid and Brain Ischemia
| Article | Year |
|---|---|
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Disease-Free Survival; Female; Follow-Up S | 2018 |
21 other studies available for valproic acid and Brain Ischemia
| Article | Year |
|---|---|
Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke.
Topics: Animals; Astrocytes; Brain Ischemia; Glial Fibrillary Acidic Protein; Gliosis; Histones; Ischemic St | 2022 |
Neuroprotective effects of sodium valproate on hippocampal cell and volume, and cognitive function in a rat model of focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cognition; Hippocampus; Infarction, Middle Cerebral Artery; Long-Term Poten | 2022 |
Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis.
Topics: Animals; Apoptosis; Brain Ischemia; Enzyme Inhibitors; Glucose; Infarction, Middle Cerebral Artery; | 2020 |
Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Ischemia; Cyclooxygenase 2 Inhibitors; Dopamin | 2018 |
Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to pre
Topics: Adult; Bone Density; Bone Remodeling; Brain Ischemia; Dietary Supplements; Epilepsy; Humans; Hyperpa | 2018 |
Neuroprotective action of valproic acid accompanied of the modification on the expression of Bcl-2 and activated caspase-3 in the brain of rats submitted to ischemia/reperfusion.
Topics: Animals; Brain Ischemia; Caspase 3; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; R | 2015 |
Valproic acid attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-pyroptosis pathways.
Topics: Animals; Anticonvulsants; Brain Ischemia; Cell Survival; Cells, Cultured; Dose-Response Relationship | 2019 |
Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain Ischemia; Disease Models, Animal; In Situ Nic | 2013 |
[Comparison of neuroprotective effects of anticonvulsant drugs in brain injury therapy].
Topics: Amines; Animals; Animals, Outbred Strains; Anticonvulsants; Brain; Brain Injuries; Brain Ischemia; C | 2012 |
Valproic acid enhances the effect of bone marrow-derived mononuclear cells in a rat ischemic stroke model.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Brain Ischemia; Combined Modality Therapy; | 2014 |
Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study.
Topics: Aged; Aged, 80 and over; Bias; Brain Ischemia; Case-Control Studies; Databases, Factual; Electronic | 2014 |
Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion.
Topics: Animals; Blood Glucose; Brain; Brain Ischemia; Hyperglycemia; Infarction, Middle Cerebral Artery; Ma | 2015 |
Na VPA-induced acute ischemic stroke in an epileptic patient with methylenetetrahydrofolate reductase gene polymorphism.
Topics: 5,10-Methylenetetrahydrofolate Reductase (FADH2); Brain; Brain Ischemia; Epilepsy; Humans; Hyperhomo | 2009 |
Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Aged; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Biological A | 2011 |
Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Basal Ganglia; Brain; Brain Ischemia; Carnitine; Cerebral I | 2011 |
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain Ischemia; Cerebral Infarction; Hypoxia-Inducible | 2012 |
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia.
Topics: Animals; Anticonvulsants; Brain Ischemia; Calcium Signaling; Carbamazepine; Electrophysiology; Excit | 2006 |
Immunogold study of effects of prenatal exposure to lipopolysaccharide and/or valproic acid on the rat blood-brain barrier vessels.
Topics: Albumins; Animals; Blood-Brain Barrier; Brain Ischemia; Cell Membrane; Cerebral Arteries; Child; Dev | 2005 |
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; Butyrates; CD11b Antigen; Cerebral Infarct | 2007 |
Moyamoya disease of childhood as a cause of recurrent cerebral ischemic attacks--a case report.
Topics: Anticonvulsants; Brain Ischemia; Carbamazepine; Cerebral Angiography; Child, Preschool; Electroencep | 1996 |
Exceptionally long absence status: multifactorial etiology, drug interactions and complications.
Topics: Aged; Anticonvulsants; Brain Ischemia; Dementia, Vascular; Drug Interactions; Epilepsy, Generalized; | 1999 |